Selective activation of 5-HT1 receptors has been shown to produce near to full suppression
of l-DOPA-induced dyskinesia (LID) in animal models of Parkinson's disease; however, a …

The serotonin system has recently emerged as an important player in the appearance of l-
DOPA-induced dyskinesia (LID) in experimental models of Parkinson's disease, as it …

Appearance of dyskinesia is a common problem of long-term l-DOPA treatment in
Parkinson's disease patients and represents a major limitation for the pharmacological …

Abstract L-3, 4-dihydroxyphenylalanine (L-DOPA) has been the standard treatment for
Parkinson's disease (PD), despite that its chronic use leads to motor fluctuations and …

Dopamine (DA) replacement therapy with l-DOPA is the standard treatment for Parkinson's
disease (PD). Unfortunately chronic treatment often leads to the development of abnormal …

Serotonin 5-HT 1A receptor agonists reduce l-DOPA-induced dyskinesia (LID) in animal
models of Parkinson's disease (PD). Here, we compared the effects of novel 5-HT 1A …

In a recent issue of Experimental Neurology, Dupre et al. report on a study performed in the
6-hydroxydopamine (6-OHDA)-lesioned rat model of Parkinson's disease (PD) which brings …

Parkinson's disease is caused by a selective vulnerability and cell loss of dopaminergic
neurons of the Substantia Nigra pars compacta and, consequently, striatal dopamine …

Serotonin transporter blockade with selective serotonin reuptake inhibitors (SSRIs) was
recently shown to counteract L-DOPA-induced dyskinesia in 6-hydroxydopamine (6-OHDA) …

Long‐term dopamine replacement therapy with l‐DOPA in Parkinson's disease often leads
to the development of abnormal involuntary movements known as l‐DOPA‐induced …